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Introduction
Death resulting from cancer has not changed significantly for 
last three decades although US government has given a lot of 
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Oxidative stress, implicated in the etiology of cancer, results 
from an imbalance in the production of reactive oxygen species 
(ROS) and cell’s own antioxidant defenses. ROS deregulate the 
redox homeostasis and promote tumor formation by initiating 
an aberrant induction of signaling networks that cause tum-
origenesis. Ultraviolet (UV) exposures, γ-radiation and other 
environmental carcinogens generate ROS in the cells, which 
can exert apoptosis in the tumors, thereby killing the malignant 
cells or induce the progression of the cancer growth by blocking 
cellular defense system. Cancer stem cells take the advantage 
of the aberrant redox system and spontaneously proliferate. 
Oxidative stress and gene-environment interactions play a sig-
nificant role in the development of breast, prostate, pancreatic 
and colon cancer. Prolonged lifetime exposure to estrogen is 
associated with several kinds of DNA damage. Oxidative stress 
and  estrogen  receptor-associated  proliferative  changes  are 
suggested to play important roles in estrogen-induced breast 
carcinogenesis. BRCA1, a tumor suppressor against hormone 
responsive cancers such as breast and prostate cancer, plays a 
significant role in inhibiting ROS and estrogen mediated DNA 
damage; thereby regulate the redox homeostasis of the cells. 
Several transcription factors and tumor suppressors are in-
volved during stress response such as Nrf2, NFκB and BRCA1. 
A promising strategy for targeting redox status of the cells is to 
use readily available natural substances from vegetables, fruits, 
herbs  and  spices.  Many  of  the  phytochemicals  have  already 
been identified to have chemopreventive potential, capable of 
intervening in carcinogenesis.
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stress in search for the cure of cancer. In the beginning, cancer 
cells are more vulnerable to chemotherapy and radiotherapy 
than normal cells, but, as the disease progresses, they lose their 
preferential sensitivity to the same treatments. All these thera-
peutic approaches as well as exposure to environmental carcin-
ogens like ionizing radiations (IR), ultraviolet (UV) exposures 
and other environmental carcinogens generate reactive oxygen 
species (ROS) in the cells, which can act in both beneficial 
and detrimental ways. ROS exerts oxidative stress in the cells 
which deregulate the body’s cellular defense system leading to 
genomic instability and cancer.1-3 Moreover, oxidative stress 
can  result  from  a  number  of  endogenous  sources,  includ-
ing the production of oxygen-free radicals by mitochondrial 
oxidative  phosphorylation.  Mitochondria  are  the  significant 
source of ROS as they are the major consumers of molecu-
lar oxygen in cells.4,5 Cellular defense system is comprised of 
several Phase II detoxification enzymes such as glutathione-
S-transferases  (GSTs),  NADP(H)  quinone  oxidoreductase 
(NQO1), Glutathione peroxidases (GPx), Catalase, superox-
ide  dismutases  (SODs),  epoxide  hydrolase,  heme  oxygenase 
(HO-1),  UDP-glucuronosyl  transferases  (UGTs),  gamma-
glutamylcysteine synthetase and many others. Expression of 
these proteins protects cells from oxidative damage and can 
prevent mutagenesis and cancer.6-11 Apart from cancer, oxida-
tive stress has been implicated in several chronic diseases and 
natural process such as aging, atherosclerosis, diabetes mellitus, 
arthritis and neurodegenerative disease including Alzheimer’s 
and Parkinson’s disease.12-17 Due to scope and limitation, this 
review will focus on the (1) Role of ROS in pathophysiologi-
cal implications of altered redox regulation in breast, prostate, 
colon and pancreatic cancer; (2) Involvement of BRCA1, as 
a protectant against oxidative stress; (3) Modulation of redox 
environment in cancer stem cells; (4) Targeting redox system 
by phytochemicals for therapeutic interventions; (5) Function 
of antioxidants, antioxidation enzymes and transcription fac-
tors in the maintenance of cellular defense system; (6) Finally 
we will discuss the future perspectives on addressing the ques-
tion; ‘Where are we leading to with these innovations and what 
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may provide improved therapeutic results as well as a preventa-
tive effect on carcinogenesis of the colorectum.30 Emerging evi-
dence also suggests that supranutritional doses of selenite could 
induce typical apoptosis in colorectal cancer cells in vitro and 
in xenograft tumors by inducing ROS. It indicates that selenite 
can activate the apoptotic machinery through redox-dependent 
activation and could be useful in cancer therapy.31
BRCA1 Functions in Oxidative Stress Responses
The breast cancer susceptibility gene, BRCA1, encodes a tumor 
suppressor protein, mutations of which account for about 40–50% 
of  hereditary  breast  cancers.32,33  In  sporadic  (non-hereditary) 
breast cancers, BRCA1 expression is absent or decreased in about 
30–40%  of  cases.  Environmental  and  genetic  factors  are  the 
important contributors of the neoplastic transformation leading 
to breast cancer. BRCA1 has several important functions and one 
of them is to render protection to the cells during oxidative stress. 
BRCA1 upregulates the expression of multiple genes involved in 
the cytoprotective antioxidant response, including GST, GPx, 
Oxidoreductases, and other antioxidant genes. Consistent with 
these  findings,  ectopic  expression  of  BRCA1  conferred  resis-
tance while BRCA1 deficiency conferred sensitivity to several 
different oxidizing agents (hydrogen peroxide and paraquat).34,35 
Evidences collected from the BRCA1 mouse model where mice 
are homozygous for full-length breast cancer-associated gene-1 
(Brca1)  deletion  and  heterozygous  for  a  p53-null  mutation   
(Brca1Δ11/ Δ 11p53+/-), display high frequency of spontaneous lym-
phoma and mammary tumor formation.36 Brca1 mutant mice 
also exhibite increased expression of Redd1, which is a develop-
mentally regulated transcriptional target of p63 and p53, dur-
ing regulation of ROS. Additionally, the same mice demonstrate 
elevated levels of ROS and subsequently they are more sensitive 
to oxidative stress induced lethality.35 In addition, in the setting 
of oxidative stress (due to hydrogen peroxide), BRCA1 shifts the 
cellular redox balance to a higher ratio of reduced to oxidized 
glutathione (GSH).34,37 Higher content of reduced glutathione 
functions in favor of redox maintenance. The identification of 
transcriptional target of several antioxidant genes that are elevated 
during BRCA1 overexpression led to the findings that BRCA1 
regulates  the  activity  of  the  antioxidant  response  transcrip-
tion factor Nrf2 and NFκB and protects cells against oxidative 
stress.34,38 This function would be consistent with the postulated 
role of BRCA1 as a caretaker gene in preserving genetic integrity 
via regulating the redox maintenance of the cells.
We have studied the antioxidant property of BRCA1 by either 
over- and or under-expression of BRCA1 in breast cancer cells. 
We have demonstrated that wild-type BRCA1 (but not a cancer-
associated mutant) significantly reduced ROS levels, determined 
by DCF fluorescence assays using flow cytometry and confocal 
microscopy.37 Figure 1 demonstrates the cellular protection func-
tion of BRCA1 during oxidative stress. MCF-7 breast cancer cells 
were transfected with either wt BRCA1 or the background vec-
tor (pcDNA3) and simultaneously all the experimental cells were 
treated with tert-butyl hydroperoxide (TBHP) (Molecular Probes; 
Carlsbard, CA) to artificially generate cellular ROS, which is 
should be done so that everybody can lead a better and relaxed 
life in this hazardous environment?’
Reactive Oxygen Species (ROS) Mediated  
Carcinogenesis
Oxidative stress promotes damage to the cell structure including 
proteins, lipids, membranes and DNA, that plays a key role in the 
development of cancer.2,12-15,18 Mitochondrial electron-transport 
chain and other oxidizing agents are the prime pathways that 
generate excess ROS in vivo, leading to several types of DNA 
damage, including depurination and depyrimidination, single- 
and double-stranded DNA breaks, base and sugar modifications 
and  DNA-protein  crosslinks.19-21  Permanent  modification  of 
genetic material resulting from the oxidative damage is one of the 
vital steps involved in mutagenesis that leads to carcinogenesis. 
Stimulation of DNA damage can either arrest or induce transcrip-
tion, signal transduction pathways, replication errors and genomic 
instability, all of which are associated with carcinogenesis.18,22,23 
The  most  frequent  DNA  mutations  caused  during  oxidative 
stress,  initiated  by  ionizing  radiation  and  other  environmen-
tal carcinogens are 7,8-dihydro-8-oxoguanine (8-Oxo-G) and 
Thymine Glycol (TG). Thymine glycol blocks transcription and 
causes cell death both in cancer and non-cancer cells. These oxi-
dized DNA products are relatively easy to generate during oxida-
tive stress and are both mutagenic and carcinogenic. Thus they 
are considered as useful markers of oxidative stress and potential 
biomarkers of carcinogenesis.24-26 To counterbalance the oxida-
tive damage from ROS, aerobic organisms have created a variety 
of antioxidant mechanisms to maintain their genomic stability. 
These mechanisms include phase II detoxification and other anti-
oxidation enzymes that act in cellular defense such as catalase 
and SOD, GPx, GST, other constitutive and inducible antioxi-
dants, DNA repair enzymes, and other cellular mechanisms of 
genomic surveillance, such as cell cycle checkpoint control sys-
tems.27 Moreover, several growth factors such as serum, insulin 
like growth factor I, or fibroblast growth factor 2 generates ROS 
in MIA PaCa-2 and PANC-1 cells, which are human pancreatic 
adenocarcinoma cells that promotes cell survival. Inhibiting ROS 
generation  with  the  antioxidants  or  NADPH  oxidase  (Nox4) 
antisense, or MnSOD overexpression would stimulate apoptosis 
in PaCa-2 and PANC-1 cells. This mechanism might play an 
important role in pancreatic cancer resistance for treatment and 
thus represent a novel therapeutic target.28 In gastrointestinal and 
colon cancer, oxidative pentose pathway (OPP) and the glutathi-
one (GSH) antioxidant defense system play an important role in 
the regulation of cell growth and apoptosis. The OPP modulate 
intracellular redox status and provides NADPH for the synthesis 
of GSH, which is responsible for the inactivation of intracellular 
ROS that induce apoptosis and cell injury. Depletion of GSH 
increases the sensitivity of cells to ROS. Therapeutic inhibition of 
the OPP and/or the GSH defense system might increase the sen-
sitivity of gastric and colon cancer cells to anti-cancer therapy.29 
Recent studies have shown that the enzymatic product of thy-
midine phosphorylase (TP) generated ROS within cancer cells 
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a putative carcinogenic metabolite of estrogen.41 This catechol 
estrogen metabolite is oxidized further to produce a reactive qui-
none via semiquinone. Oxidative stress and estrogen receptor-
associated proliferative changes are suggested to play important 
roles  in  estrogen-induced  breast  carcinogenesis.42-44  Treatment 
of the immortalized human breast epithelial cells (MCF-10F) 
with  17β-estradiol  (E2),  4-hydroxyestradiol  (4-OHE2)  or 
2-hydroxyestradiol  (2-OHE2)  induces  phenotypical  changes 
indicative  of  neoplastic  transformation.45  Although  the  pre-
cise molecular mechanisms by which E2 induces breast cancer 
have not been completely understood, the estrogen implication 
in breast cancer has been associated mostly with the estrogen 
receptor46,47 that mediates cell proliferation. The direct role of 
estrogens as tumor initiators has been supported by the evidence 
that E2, catechol estrogens (CEs) and their quinone derivatives 
exerts oxidative stress that lead to various types of DNA damage, 
including single strand breaks as well as stable and depurinating 
DNA adducts.48,49 2-OHE2 and 4-OHE2 are the two catechol 
metabolites of estrogens that could be oxidized to CE quinones 
(CE-Q) that may react with DNA. Physiologic concentrations 
of estradiol (E2) have also been reported to cause a decrease in 
catalase activity followed by an increase in glutathione peroxidase 
(GPx) activity, in MCF-10A breast epithelial cells.50,51 Moreover, 
thioredoxin (Trx) and thioredoxin reductase (TrxR) are shown 
to modulate H2O2 levels and the activity of estrogen in estro-
gen responsive breast cancer cells.52 Oxidative stress can change 
the structure and function of estrogen receptor and progester-
one receptor (PR), altering the biology and clinical outcome of 
endocrine  responsive  (ER-positive)  breast  cancer.53,54  A  subset 
of estrogen/ER-responsive breast cancer genes that are linked to 
detected  by  using  Carboxy-H2DCFDA  (Green)  (Molecular 
probes (I36007), Carlsbard, CA). This figure demonstrates that 
ectopic expression of BRCA1 significantly reduces the forma-
tion of ROS triggered by TBHP (third column) when compared 
to vehicle and pcDNA3 plasmid transfection (first and second 
column). Furthermore, expression of redox factor 1/AP endonu-
cleases 1 (Ref1/APE1) in breast cancer cells, which has a dual role 
of redox regulation in cells and lyase activity in stimulating base 
excision repair (BER) pathway, inhibits the generation of ROS 
and promotes cell survival against oxidative stress, rendered by 
either stress producing agents.39,40 The BRCA1 and Ref1/APE1 
pathways for reduction of ROS levels appear to exhibit cross-talk 
in protecting the cells from stress. BRCA1 also reduced the lev-
els of protein nitration that exerts nitrative stress in the cells by 
forming harmful 3-Nitrotyrosine during H2O2-induced oxida-
tive damage to proteins.37 H 2O2 caused modest but detectable 
increases in the levels of 8-oxo-G and thymine glycol (TG) modi-
fication in DNA. Wt BRCA1 reduced, while BRCA1-siRNA fur-
ther increased the 8-oxo-G and TG levels in H2O2-treated cells 
indicating BRCA1 involves in stimulating DNA repair process to 
repair the oxidative lesions.37
Oxidative Stress Mediated Estrogen Receptor  
Activity in Breast Cancer
Estrogens play a crucial role in the development and evolution 
of  human  breast  cancer.  Epidemiological  evidence  indicates 
that prolonged lifetime exposure to estrogen is associated with 
elevated  breast  cancer  risk  in  women.  Estrogen  is  converted 
by  cytochrome  P450  1B1  to  4-hydroxyestradiol  (4-OHE2),   
Figure 1. Wt BRCA1 downregulates the production of ROS in MCF-7 breast cancer cells. Cells were transfected either with background vector 
(pcDNA3) or with wt BRCA1 plasmid. Forty-eight hours post transfection all the cells were treated with 100 μM of ROS producing agent TBHP 
(tert-butyl hydroperoxide) in a serum free medium. Levels of ROS were detected through confocal microscopy using carboxy-H2DCF-DA fluorescence 
(first row). Second row is the phase picture of all the cells that are used for confocal staining. Decrease in the stain intensity in BRCA1 transfected cells 
compared to vehicle and background vector transfected cells depicts an important function of BRCA1 in protecting cells from oxidative damages.26  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 1
Targeting Redox Mediated Signaling Cascade  
Leading to Cell Death in Cancer
Cancer cells have been found to be in a state of redox imbalance, 
an alteration in the homeostasis between oxidants and antioxi-
dants, resulting in increased oxidants within the cell. Oxidative 
stress due to the chronic over-exposure to ROS is thought to 
contribute to a variety of processes, including aging, degenera-
tive diseases, and cancer.12-16 On the other hand, ROS also play 
an essential role as secondary messengers in the normal regula-
tion of a variety of physiological processes, suggesting that their 
production is a double-edged sword. Oxidative stress can induce 
positive  responses  such  as  cellular  proliferation  or  activation, 
as well as negative responses such as growth inhibition or cell 
death. Cellular redox status is maintained by several intracellu-
lar redox-regulating molecules, including thioredoxins (TRX).69 
TRX is one of the key regulators of signaling in the cellular 
responses against various stresses. TRX demonstrates a cytopro-
tective action against oxidative stress-induced apoptosis as well as 
induces growth-promoting effect as an autocrine growth factor. 
Moreover, TRX is involved in the regulation of protein-protein 
or protein–nucleic acid interactions through its redox nature of 
the cysteine residues. TRX translocates from the cytosol into 
the nucleus due to a variety of cellular stresses, to regulate the 
expression of various genes through the redox factor-1 (Ref-1/
APEX1).70 Glutathione (GSH)/Glutaredoxin (GRX) system also 
maintains the redox homeostasis in the cells but it is dependent 
on the TRX redox regulation.71 GRX is a small dithiol protein 
involved in various cellular functions, including the redox reg-
ulation of certain enzyme activities via its disulfide exchange 
reaction. Overexpression of GRX, protect cells from hydrogen 
peroxide (H2O2)-induced apoptosis by regulating the redox state 
of the cell. Thus molecules or enzymes that can penetrate the 
redox environment of the cancer cells will be beneficial for killing 
the same. Incidentally stress levels in some tumor cells are actu-
ally masked by the activation of anti-oxidation/anti-apoptotic 
signaling. If this molecular shield can be removed in the cancer 
cells, death signals can be reinstated by inducing stress and cells 
can be forced to undergo apoptosis again. A number of examples 
imply that this can be achieved. For example, non-small-cell lung 
carcinoma cells become more resistant to cytotoxic agents such as 
cisplatin, doxorubicin and etoposide due to the elevated levels of 
Her-2/neu expression but when Her-2/neu signaling was inhib-
ited, these cells become re-sensitized to these agents.72 Similarly, 
the ectopic expression of a mutated EGFR, in advanced glioma, 
exhibit resistance to cisplatin due to reduced apoptosis. Blocking 
EGFR signaling in these cells restores their cisplatin sensitivity.73 
Blocking Her-2 with Herceptin (Trastuzumab) sensitizes highly 
drug-resistant breast cancer cells to cytotoxic drugs.74 In fact, the 
combination of chemotherapy with cellular redox system modi-
fiers has shown promising results in clinical trials. How these 
combined therapies modulate ROS and stress kinase pathways 
at the cellular level has not been determined yet. The study of 
stress signaling has proved to be instructive in explaining recent 
advances in cancer therapy and should facilitate the development 
of improved anticancer strategies.
cell growth and invasion pathways were identified and associated 
with loss of PR.55,56 Intracellular proteins that are most suscep-
tible to oxidant-induced structural and functional damage are 
redox-sensitive zinc finger transcription factors such as Sp1 and 
ER. Zinc finger cysteine residues of ER are readily oxidized dur-
ing stress, eliminating their DNA-binding activity. Failure of 
DNA-binding activity of ER has been found in up to 30–35% 
of all ER-positive breast cancers and that correlated with loss of 
PR expression. Both, Sp1 and ER-α DNA-binding and transac-
tivating functions are needed for optimal estrogenic stimulation 
of genes such as PR and Bcl2. ER-positive breast cancers would 
exhibit suppressed expression of these estrogen-inducible genes 
during oxidative stress.
Redox Status in Cancer Stem Cells
Studies have shown that redox balance plays an important role in 
the maintenance of stem cell self-renewal and in differentiation. 
Very little is known about the redox status in cancer stem cells. 
Normal haemopoietic stem cells and normal mammary epithe-
lial stem cells maintained lower levels of ROS than their mature 
progeny to prevent cellular differentiation and maintain long-
term self-renewal.57-59 A newly identified subpopulation of cells, 
known as ‘cancer stem cells’, are responsible for the reoccurrence 
of tumor following chemotherapy. These cells are highly drug 
resistance and one can hypothesize that these cells use redox reg-
ulatory mechanisms to escape the cell death by several anticancer 
agents.60-65 Cancer stem cells actually maintain both the stem-
ness nature and cancer cell characteristics for growth and survival 
and probably they share some very common characteristics like 
normal stem cells in redox regulation. Evidences are that subsets 
of cancer stem cells in human and murine breast tumors contain 
lower ROS levels, similar to normal stem cells, than the corre-
sponding non-tumorigenic cells.57 This low level of ROS seems 
to  be  associated  with  elevated  expression  of  ROS-scavenging 
molecules, which may contribute to tumor radioresistance. We 
believe BRCA1 has a role in modulating cancer stem cells. The 
major transcription factor responsible for the stemness nature of 
the cells is the Forkhead Box Os (FoxOs) that upregulates the 
expression of SOD and catalase.66,67 Biological properties of the 
cancer stem cells renders that these cells might have an elevated 
antioxidation enzymes pool to maintain reduced levels of ROS 
like normal stem cells. On the other hand, this high antioxidant 
capacity also favors the survival of the cancer stem cells and drug 
resistance. Moreover, some stem cells reside in a relatively low 
oxygen microenvironment that might also limit the endogenous 
ROS production. Thus cancer stem cells in a hypoxic microenvi-
ronment may be relatively resistant to radiotherapy and chemo-
therapy with redox-cycling agents since their cytotoxicity requires 
the availability of local oxygen. It is thus crucial to first determine 
the redox status in cancer stem cells compared with normal stem 
cells and with cancer cells in tumors.57,68 Discovery of the main 
molecular signaling pathway that maintains the redox nature 
in cancer stem cells might provide a possibility to abrogate the   
survival mechanisms in these cancer stem cells and allow the 
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are known for their high therapeutic potential for ages. Spices 
are now receiving increasing attention as many of them have 
been shown to have anti-carcinogenic properties. Saffron, Clove, 
Cardamom and Cinnamon are highly aromatic spices, commonly 
used in Asian, Arab and some Scandinavian cuisines. We and 
others have demonstrated several anti-carcinogenic activities of 
these spices against several cancers by upregulating several phase 
II detoxification enzymes, antioxidants and reducing the lipid 
peroxides in the cells.82-87 Additionally, garlic, which is whole 
food used all over the world demonstrates a formidable prophy-
lactic and therapeutic medicinal property.85 Garlic extracts inhib-
its the oxidative modification of lipids induced by DMBA, thus 
protecting cells from injury by the oxidized molecules.85 Oral 
administration with aqueous infusion of garlic and cardamom in 
addition to the DMBA treatment to the swiss albino mice dem-
onstrate downregulation of COX2 and p53 (tumor suppressor) 
expression when compared to the DMBA treated mice only indi-
cating reduction of inflammation related abnormalities in the 
phytocompounds treated mice. These phytocompounds delayed 
the formation of skin papillomas in animals and simultaneously 
decreased the size and number of papillomas demonstrating their 
beneficial effects.84,85
Redox Sensitive Transcription Factors Involved  
in Oxidative Stress
The concept of “Redox Regulation” in the field of cancer pre-
vention is emerging to understand the mechanisms behind the 
pathogenesis of several disorders including tumor initiation and 
malignant transformation.88,89 Redox sensitive transcription fac-
tors are the key players in regulating several pathways that lead 
to carcinogenesis. Transcription factors/activators are a group of 
proteins that bind to specific consensus sequences (cis elements) 
in  the  promoter  regions  of  downstream  target/effector  genes 
and either transactivate or repress effector gene expression. The 
change in the expression of the effector genes eventually leads 
to several biological modifications such as proliferation, growth 
suppression, differentiation or senescence. Furthermore, redox-
induced  biochemical  alterations  sometimes  lead  to  change  in 
the biological functions of these proteins. Therefore, differen-
tial regulation of these transcriptional activators, which in turn, 
regulate many target/effector genes, may provide an additional 
mechanism by which small antioxidant molecules play protective 
roles in anti-cancer processes and thus have an important impact 
on drug discovery and therapy for the inhibition of cancer. This 
section will focus on the redox regulation of transcription fac-
tors/activators with emphasis on Nrf2 and NFκB that modulate 
during oxidative stress.
Nrf2
The role of the activation of Nuclear factor-erythroid-2-related 
factor 2 (Nrf2) transcription factor and its repression by Kelch-
like ECH-associated protein 1 (Keap1) during oxidative stress 
has been well established.90-92 The basal expression as well as 
the induction of genes encoding phase II enzymes are mediated 
Phytochemicals as Anti-Cancer Chemopreventive 
Compounds that Targets Redox Regulations
Considering the burden of health-care cost as a major global 
concern,  dietary  chemoprevention  provides  an  inexpensive, 
readily applicable and easily accessible approach to cancer con-
trol and management and at present it is a hot area of research. 
Strengthening of cellular defense mechanism or restoration of 
stress-response signaling by administrating dietary phytonutri-
ents  provides  an  important  strategy  for  cancer  chemopreven-
tion. Currently antioxidant activity is the most common in vitro 
parameter used to assess or predict potential benefits of plant 
derived compounds. However, correlations between in vitro anti-
oxidant activity and actual health benefits are unknown. Such in 
vitro antioxidant data ignore other potentially beneficial or harm-
ful effects of phytochemicals like modification of enzyme activity 
and/or cell signaling pathways. There are several compounds we 
are working with, that target the redox system of the cancer cells 
either by inducing ROS-mediated apoptosis or prevent the cells 
from exogenous or endogenous sources of ROS by upregulating 
cellular defense system and inhibiting the cancerous growth.
Indole-3-carbinol  (I3C),  a  phytochemical  from  crucifer-
ous vegetables, is of interest because a diet rich in cruciferous 
vegetables  is  associated  with  a  reduced  risk  of  several  tumor 
types, such as breast cancer. In the acidic environment of the 
stomach, I3C undergoes hydrolysis to a number of products, 
including a dimeric product, 3,3'-diindolylmethane (DIM), its 
major active metabolite.75 Both these phytochemicals stimulate 
BRCA1 in breast and prostate cancer cells and has been shown 
to protect cells against oxidative stress mediated by H2O2 and 
γ-radiation.75,76 Genistein (4,5,7-trihydroxyisoflavone) was iden-
tified as the predominant isoflavone in soybean enriched foods, 
which  comprises  a  significant  portion  of  the  Asian  diet,  has 
been shown to inhibit prostate carcinogenesis in animal mod-
els. Genistein has antioxidant effects and protects cells against 
ROS by scavenging free radicals, inhibiting the expression of 
stress-response related genes.76 Furthermore, genistein is a pow-
erful inhibitor of NFκB, Akt and PTK signaling pathways, all 
of which are important for cell survival.77 Curcumin, on the 
other hand, is a diferuloylmethane, derived from the rhizomes 
of turmeric. Curcumin targets the Nrf2-ARE signaling pathway 
to induce phase II detoxifying enzymes on an event of oxida-
tive stress.38,78 Addition of curcumin disrupts the Nrf2-Keap1 
complex, leading to elevated Nrf2 binding to ARE and subse-
quent increase in the expression and activity of HO-1 in por-
cine renal epithelial proximal tubule (LLC-PK1) cells and/or rat 
kidney epithelial (NRK-52E) cells via activation of p38 MAP 
kinase. UDP-glucuronosyltransferase (UGT) isozymes catalyze 
detoxification of numerous chemical toxins present in our daily 
diet and environment, which give rise to ROS, by conjugation 
to glucuronic acid. Curcumin modulates the activity of cellu-
lar UGT1A7 and UGT1A10 and increases the bioavailability of 
other compounds such as Genistein or Diadzein in the cells that 
has an inhibitory effect on cancer.79-81
Whole food and spices demonstrate excellent source of mix-
ture of compounds that targets the redox system of the cells and 28  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 1
Nrf2 and members of the glutathione-S-transferase (GST) mu 
family are extensively decreased in human prostate cancer. Loss of 
Nrf2 initiates a detrimental cascade of reduced GST expression, 
elevated ROS levels and ultimately DNA damage associated with 
initiation of cellular transformation in the prostate gland.103
NFκB
The NFκB family of redox transcription factors has been acti-
vated in many malignancies including breast, prostate, pancreas, 
colon, leukemia, lymphoma etc. NFκB activation results in devel-
opment and/or progression of cancer by regulating the expression 
of genes involved in cell growth and proliferation, anti-apoptosis, 
angiogenesis and metastasis.104-108 The NFκB transcription fac-
tors are composed of homodimers or heterodimers of Rel pro-
teins, which interact with inhibitory proteins, members of the 
IκB family. As a consequence of binding to cytoplasmic IκBs, 
the nuclear localization signal of the NFκB dimer is masked 
and NFκB is sequestered in the cytoplasm. In response to proin-
flammatory cytokines such as tumor necrosis factor (TNF) and 
interleukin-1 (IL-1), bacterial lipopolysaccharide (LPS) or viral 
double-strand RNA (dsRNA), the IκBs are rapidly phosphory-
lated and then undergo ubiquitination and proteolysis by the 26S 
proteasome, resulting in release and translocation of NFκB to the 
nucleus, where it activates transcription of specific target genes. It 
is suggested that NFκB activity is regulated by intracellular ROS 
levels, but the exact molecular mechanism involved in this regu-
lation remains to be elucidated.25,109,110 For example it was shown 
that ROS overproduced by 4-OHE2 increased the nuclear trans-
location of NFκB and its DNA binding through induction of 
IκB kinase alpha and IKKβ activities that contribute to neoplas-
tic transformation of human mammary epithelial cells (MCF-
10A).110 Similar effect has been observed with sodium arsenite 
that mimics the effects of estradiol and induces cell proliferation 
in the estrogen responsive breast cancer cell line MCF-7. Sodium 
arsenite stimulate ROS generation followed by oxidative DNA 
damage. It also induces HO-1 and c-Myc proteins as well as 
NFκB activation and cell proliferation in human breast cancer 
MCF-7 cells.111
In certain cell types, such as Wurzburg subclone of T cells, 
L6 skeletal muscle myotubes, human breast MCF-7 and 70Z/3 
pre-B  cells,  hydrogen  peroxide  (H2O2)  was  shown  to  be  an 
effective inducer of NFκB activation, but in other cell types it 
does not.112,113 Intracellular level of reduced glutathione (GSH), 
which may differ from one cell type to another, may be crucial 
for H2O2-induced NFκB response during oxidative stress. GSH 
is the major intracellular thiol and an exellent ROS scavenger. 
N-acetyl-L-cysteine (NAC) is a nontoxic compound that protects 
cells from oxidative damage and Buthionine-Sulfoximine (BSO) 
is a drug that causes GSH depletion since it selectively inhibits 
glutamylcysteine synthetase, the enzyme responsible for GSH 
synthesis.  Preincubation  with  NAC  abolished  H2O2-induced 
NFκB activation in the Wurzburg T cells, while preincubation 
with BSO demonstrate detectable H2O2-induced NFκB activa-
tion in HeLa cells.114,115 Several indirect lines of evidence suggest 
a role for ROS as a common and critical intermediate for various   
by means of the antioxidant response element (ARE).93 ARE 
is a cis-acting enhancer sequence that transcriptionally regu-
lates these genes, to maintain the cellular redox status and to 
protect against oxidative damage. Several studies have demon-
strated that Nrf2 is involved in the regulation of ARE-mediated 
gene expression.90,94 Nrf2 is a member of basic leucine zipper 
transcription factors and is essential for the coordinated induc-
tion of genes that encodes stress-responsive or cytoptotective 
enzymes and related proteins, such as NQO1, SODs, GSTs, 
GPx, HO-1, glutamate cysteine ligase (GCL), catalase and thi-
oredoxin. Nrf2 plays an essential role in maintaining cellular 
homeostasis and hence represents a critical target for prevention 
of oxidative stress- or inflammation-associated carcinogenesis. 
Under normal physiological conditions, Nrf2 forms an inactive 
complex with the negative regulator, Keap1 which controls the 
subcellular localization and steady-state levels of Nrf2. Cysteine 
residues present in Keap1 function as redox sensors. Oxidation 
or chemical modification of some of the highly reactive cysteine 
residues facilitates the dissociation of Nrf2 from Keap1 and sub-
sequent nuclear translocation.95-97 Therefore, Nrf2 constitutes a 
unique redox regulator that can be modulated in response to 
redox imbalance caused by oxidative and electrophilic stresses. 
Evidences gathered from the Nrf2-deficient mice, demonstrate 
a strong redox imbalanced system that failed to induce genes 
responsible for carcinogen detoxification and protection against 
oxidative stress.98 In addition, levels of pro-inflammatory medi-
ators, such as cyclooxygenase-2 (COX-2), inducible nitric oxide 
synthase (iNOS), interleukin (IL)-1β, IL-6, and tumor necrosis 
factor alpha (TNFα), were significantly elevated in the colonic 
tissues of Nrf2-/- mice as compared to their wild-type counter-
parts.99 All of these conditions described above induce genera-
tion of ROS in the cells. Thus, it would be highly advantageous 
to explore the cytoprotective gene expression induced by anti-
cancer  compounds  with  the  Nrf2-Keap1  system  as  a  prime 
molecular target.
In breast cancer cells (MCF-7, T47D and MCF-10A), Nrf2 
plays an important role in suppressing oxidative stress rendered 
by  either  paraquat  or  H2O2  by  upregulating  several  phase  II 
detoxification enzymes. On the other hand ectopic expression 
of wtBRCA1 also stimulate the expression of Nrf2 in the same 
cells thus indicate an important function of Nrf2 in breast can-
cer.34,75,100 Additionally, retinoic acid (RA), which is an analogue of 
Vitamin A, has been shown to inhibit breast cancer cell growth101 
although it is clinically hindered by toxicity possibly related to 
oxidative  stress.  At  relatively  low  concentrations  RA  inhibits 
Nrf2 and the expression of its target antioxidation enzymes, thus 
possibly raises the toxicity. Nrf2 enhancement as a therapeutic 
target of retinoid toxicity awaits further investigation.102 Gamma-
tocopherol (γ-T) alone or in combination with alpha-tocopherol 
diet to mice [murine prostate cancer model (TRAMP)] has been 
shown to suppress prostate carcinogenesis by significantly upreg-
ulating the expression of Nrf2 and its related detoxifying and 
antioxidant enzymes, thereby suppressing prostrate intraepithe-
lial neoplasia (PIN) and tumor development.7 More evidences of 
Nrf2 involvement in prostate cancer is demonstrated by multiple 
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and Caspase 3. It also suppresses the expression of extracellular 
regulatory kinase-2 (ERK-2) and inhibits the expression of ROS 
in the same colon cancer cells.122 Isothiocyanates that are found 
in cruciferous vegetables such as broccoli, brussels sprouts, cau-
liflower and cabbage, suggest that cruciferous vegetable intake 
may lower overall cancer risk generated during oxidative stress, 
including colon and prostate cancer due to inactivation of NFκB 
signaling pathway.
Oxidative Stress Signaling through MAP Kinases
Mitogen-activated protein kinases (MAPKs) are the key players 
of kinase cascades that connect extracellular signals to specific 
transcription factors, thereby converting these signals into cellu-
lar responses. In mammalian systems, there are three subgroups 
of  MAPKs:  ERKs  (extracellular  signal-regulated  kinases), 
JNKs (c-Jun N-terminal kinases) and p38 MAPKs. Growth 
factors  and  mitogens  use  the  Ras/Raf/MEK/ERK  signaling 
cascade to transmit signals from their receptors to regulate gene 
expression and prevent apoptosis in normal condition.123,124 The 
MAPK signaling cascade is activated by a wide variety of recep-
tors involved in growth and differentiation including receptor 
tyrosine kinases (RTKs), integrins and ion channels. This path-
way has been reported to be activated in over 50% of acute 
myelogenous  leukemia,  acute  lymphocytic  leukemia  and  are 
frequently activated in breast, prostate cancers and other can-
cer types.124-126 Under optimal growth conditions, transiently 
elevated ROS levels confer a growth advantage to tumor cells. 
However, exposure of these cells to anticancer agents induces 
a prolonged increase in ROS levels resulting in potentiation 
of apoptosis. Thus ROS modulates the ability of stress kinases 
to stimulate cell growth or cell death and it depends on signal 
intensity and signal duration.127,128 This idea has been nurtured 
to explain the complex nature of ERK signaling in cell cycle reg-
ulation and in stress activated protein kinase signaling (SAPK). 
Transient, reduced activity of SAPK promotes cell proliferation, 
whereas persistent, increased activity results in cell killing.129,130 
Conversely, in drug-resistant tumors, phase II enzymes or other 
antioxidant defenses are often upregulated, shielding cells from 
apoptosis. ASK1, an upstream regulator of SAPKs, is inhibited 
in normal cells through its association with thioredoxin, which 
is an antioxidant capable of metabolizing ROS. Increased levels 
of ROS lead to the dissociation of this complex and thereby 
facilitate the activation of ASK1 and subsequently SAPKs.131,132 
A  similar  redox  control  has  been  identified  for  JNK  where 
increased level of ROS triggers the detachment of JNK associ-
ated glutathione-S-transferase-π (GSTp) and thereby facilitat-
ing  JNK  activation.133  Moreover,  ROS-dependent  activation 
of JNK may also lead to knock down of a JNK phosphatase 
via an unknown mechanism linking ROS and stress induced 
kinases an important player in cancer cell growth. Recently it 
was  demonstrated  that  mammalian  stanniocalcin-1  (STC1), 
which is a glycoprotein, has been implicated in various biologi-
cal processes including angiogenesis and its aberrant expres-
sion has been reported with hormone responsive cancers such 
as breast, prostate and ovarian cancer. During oxidative stress 
NFκB-activating signals.25,109,110,116 This conclusion is based largely 
on the inhibition of NFκB activation by a variety of antioxidants 
and by overexpression of antioxidant enzymes.117 These reagents 
have been reported to block NFκB activation in many instances, 
although the extent of inhibition appears to vary depending on 
cell type and duration of the stimulus. Overexpression of man-
ganese superoxide dismutase (MnSOD) or GPx abolished NFκB 
activation induced by TNF, LPS, PMA and H2O2. AP-1 activity, 
JNK activation and apoptosis induced by TNF were also sup-
pressed by overexpression of MnSOD.118 Molecularly, oxidative 
stress stimulate the formation of the slow migrating ubiquitinated 
forms of the NFκB subunit, IκBα, in SDS-polyacrylamide gel, 
which rapidly degrades unless cells were treated with the pro-
teasome inhibitor.119 Addition of antioxidants or overexpression 
of peroxidases in the same stressed cells blocked IκBα degra-
dation induced by TNF, PMA and LPS. Taken together, these 
data suggested that post translational modification of IκBα and 
subsequent degradation might be the step that is responsive to 
oxidative stress.
In  prostate  cancer  cells,  a  constitutive  NFκB  activity  was 
reported either due to increase in activity of IκB kinase complex 
or by regulating the expression of c-myc, cyclin D1 and IL6 in 
the same cells that deregulate the redox homeostasis in the cells. 
Additionally, expression of androgen receptor was found to be 
inversely proportional with the activity of NFκB. Several natu-
ral products have been successfully tested against prostate cancer 
progression but the most effective ones are the soy isoflavones 
such as, genistein and daidzein. Genistein acts as antioxidant 
and simultaneously inhibits the TNFα induced activation of the 
redox-sensitive transcription factor, NFκB, in these cells as well 
as in human lymphocytes. Surprisingly both anti apoptotic and 
pro apoptotic function of NFκB have been reported in prostate 
cancer cells that make it difficult to understand the role of NFκB 
in prostate cancer cells. Similarly, activation of NFκB signaling 
is responsible in ROS mediated pancreatic cancer progression. 
Pancreatic stellate cells (PSC) play a pivotal role in the develop-
ment of pancreatic fibrosis, which is a characteristic feature of 
chronic pancreatitis and of desmoplastic reaction associated with 
pancreatic cancer. PSCs activation is important for the develop-
ment of anti-fibrosis therapy. Recent studies have identified key 
mediators of stimulatory and inhibitory signals such as peroxi-
some  proliferator-activated  receptor-gamma  (PPAR-γ),  Rho/
Rho kinase, NFκB, MAP kinases, phosphatidylinositol 3 kinase 
(PI3K) and reactive oxygen species (ROS) might be candidates 
for the development of anti-fibrosis therapy targeting PSCs.120 In 
human leukemic cells (HL-60) and colon adenocarcinoma cells 
(LS-174 and WiDr), β-carotene alone or in combination with 
α-tocopherol or NAC, is associated with significant increase in 
ROS production and in oxidized glutathione (GSSG) content. 
These effects were always accompanied by a sustained elevation 
of NFκB and by a significant inhibition of cell growth that sug-
gests that NFκB induced by β-carotene is involved in the growth-
inhibitory and proapoptotic effects of the carotenoid in leukemia 
and  colon  adenocarcinoma  cells.121  Moreover,  diallyl  sulfide 
(DAS), an organosulfur component of garlic, induces apopto-
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phytochemical, Capsaicin, originated from Red Pepper that has 
anticarcinogenic, antimutagenic or chemopreventive properties, 
inhibits cell growth and induces apoptosis through ROS gen-
eration.  Capsaicin  also  stimulated  the  MAP  kinase  cascades, 
ERK, JNK and p38 MAPK, to demonstrate its antiproliferative 
effect but it does not activate p38 MAPK.144 Lastly a new ionic 
Pd(II) complex, with the metal center coordinated to two dif-
ferent chelating ligands, the pure curcumin (from turmeric) and 
the 4,4'-dinonyl-2,2'-bipyridine, has been shown to inhibit both 
cell growth and apoptosis in several human prostate cancer cells, 
(LnCaP, PC3, and DU145) through the production of ROS and 
JNK phosphorylation associated with GSTp1 downregulation.145 
Thus exploiting the MAP kinase pathway could be an important 
step towards inhibition of the occurrences of prostate cancer.
On the basis of what discussed above in regards to the role of 
oxidative stress in carcinogenesis with emphasis to breast, pros-
tate, colon and pancreatic cancer we generated a pictorial model 
(Fig. 2) using Motifolio Tool kit (www.motifolio.com). We tried 
to demonstrate the crosstalk between the molecular mechanisms 
that occur during the anti-carcinogenic actions of several com-
pounds  by  exploiting  Nrf2,  NFκB  or  MAP  kinase  pathways 
when the cells are under oxidative stress.
Concluding Remarks and Future Perspectives
Redox adaptation is an important concept that cancer cells under-
take to survive, under persistent endogenous ROS stress and become 
resistant to certain anticancer agents. Redox-modulating strategies 
to target these biochemical properties of cancer cells will be a fea-
sible therapeutic approach that may enable therapeutic selectivity 
and to overcome drug resistance. One of the best strategies is to 
increase the ROS metabolizing capacity of the agents (antioxidants 
and antioxidation enzymes) that subsequently suppress the tumor 
growth. But, there are reports that using antioxidants in clinical 
trials are associated with increased cancer incidences, probably due 
to the inhibition of ROS mediated apoptosis of cancer cells. In 
addition, there is experimental evidence that antioxidants (e.g.,: 
paclitaxel and bortezomib) and radiation therapy, could actually 
decrease the ROS-mediated anti-tumor activity of the anticancer 
agents.146,147 An alternative approach is to treat cancer cells with 
pharmacological agents that have pro-oxidant properties, which 
increase ROS generation or abrogate the cellular antioxidant sys-
tems in the tumor itself. Cancer stem cells are highly resistant to 
anticancer drugs and might use the same redox adaptation as nor-
mal stem cells, for their survival. An approach that can break this 
redox adaptation by depleting the main antioxidant pool from the 
cells might be beneficial to eliminate the cancer stem cells. Studies 
showing that a compound known as TDZD-8 (4-benzyl-2-methyl-
1,2,4-thiadiazolidine-3,5-dione) can induce the depletion of thi-
ols, leading to a rapid accumulation of ROS and selectively kill 
leukaemic cells expressing stem-cell markers with minimal toxicity 
to normal haemopoietic stem cells,148 highlights this as an impor-
tant research direction.
Molecularly,  it  has  become  clear  that  cancer  results  from 
alterations and aberrations in several hundred genes, indicating 
that a tumor cell uses multiple pathways to survive and thrive.   
the expression of STC1 increased several folds that are associated 
with decrease in ERK1/2 activation in mouse MEFs.134
Several natural phytochemicals exploit the signaling cascades 
of MAP kinases to exert its effects on the modulation of cancer 
initiation and progression. Kaempferol is a flavonoid that reduces 
the cell viability of breast cancer cells by inducing ROS medi-
ated apoptosis and ERK activation as demonstrated by 3D cul-
ture conditions.135,136 On the other hand, Acacetin, which is a 
natural flavone, and stimulate apoptosis in MCF-7, breast cancer 
cells that is mediated by activation of caspases, ROS generation, 
mitochondria-mediated cell death signaling and the induction of 
SAPK/JNK1/2-c-Jun signaling pathway.137 Exposure of MCF-7 
and MDA-MB-231 breast cancer cells to kotomolide A (KTA), 
a new butanolide constituent, resulted in cellular GSH reduc-
tion and ROS generation, accompanied by JNK activation and 
apoptosis.138 When comes to pancreatic cancer, it is very aggres-
sive and unresponsive to treatments due to its resistance to apop-
tosis. Growth inhibition of pancreatic cells is dependent on the 
efficiency of scavenging ROS as well as effective inhibition of 
ERK1/2 signaling pathway activation as demonstrated by using 
the free radical scavenger NAC or the MEK/ERK1/2 inhibitor 
(PD98059). Moreover, ERK1/2 induction is dependent on ROS 
production as demonstrated by a complete removal of ERK1/2 
phosphorylation by NAC.139 Thus ROS act as prosurvival, anti-
apoptotic factor in pancreatic cancer cells. Moreover, treatment 
of SW620 (colon cancer cells) with berberine, which is a major 
constituents of Coptidis Thizoma, resulted in activation of apop-
tosis by phosphorylation of JNK and p38 MAPK, as well as gen-
eration of the ROS.140 Furthermore, proline oxidase (POX), that 
often considered as a ‘housekeeping enzyme’, induce apoptosis 
through both intrinsic and extrinsic pathways and is involved in 
nuclear factor of activated T cells (NFAT) signaling and regula-
tion of the MEK/ERK pathway in colon cancer cells. It is sug-
gested that, as a nutrition factor, POX may modulate apoptosis 
signals induced by p53 or other anti-cancer agents and enhance 
apoptosis in stress situations.141
Activating Map kinase pathways in prostate cancer cells is 
often beneficial to stimulate apoptosis and inhibition of growth. 
Melatonin,  the  main  secretory  product  of  the  pineal  gland, 
inhibits the growth of prostate cancer cells (LNCaP) and pro-
motes apoptosis via MAPKs, which are closely associated with 
apoptosis and survival. Melatonin also activates JNK and p38 
kinase whereas extracellular signal-regulated kinase (ERK) was 
not responsive to melatonin. Thus, melatonin may be of prom-
ise for anti-prostate cancer strategies that will utilize the MAP 
kinase pathways.142 Moreover the well known AKT/mammalian 
target of rapamycin (AKT/mTOR) and ERK MAPK signaling 
pathways have been shown to participate in prostate cancer pro-
gression. A combinatorial therapy using rapamycin, an inhibi-
tor of mTOR, and PD0325901, an inhibitor of MAPK kinase 
1 (MEK; the kinase directly upstream of ERK), inhibits cell 
growth in cultured prostate cancer cells. Furthermore, analyses 
of human prostate cancer tissue microarrays demonstrated that 
AKT/mTOR  and  ERK  MAPK  signaling  pathways  are  often 
deregulated  during  prostate  cancer  progression  in  humans.143 
In androgen-independent prostate cancer (PC-3) cells, natural www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  31
phytochemicals  and  their  biological  properties  depends  on 
their presence at the time and site of the damage. Another issue 
of concern is whether purified phytochemicals have the same 
protective effects, as do the whole food or mixture of foods in 
which these compounds are present. The current knowledge 
base teaches us that they are generally more effective when con-
sumed as whole foods.
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A  definitive  role  of  selected  dietary  naturally  occurring   
products for prevention and treatment of cancer is now getting 
high popularity. The challenge is how best to use this informa-
tion for cancer prevention in populations with differing can-
cer risk. One way to address this problem is to design potent 
mixture of several phytochemicals from plant and fruit sources 
that could have an additive and synergistic effect to inhibit 
several  molecular  pathways  required  by  cancer  cells  to  sur-
vive. Such cocktails will have greater likelihood for producing   
cancer  chemopreventive  effects  in  humans  than  individual 
components. Bioavailability is one of the critical issues to be 
discussed  even  before  considering  the  beneficial  effects  of 
several  phytochemicals  because  metabolism  of  the  dietary 
Figure 2. A putative model for oxidative stress induced interactions in carcinogenesis. Reactive oxygen species (ROS) mediated oxidative stress 
either by environmental carcinogens such as UV and ionizing radiation or by mitochondrial metabolism exerts several effects on DNA damage and 
generation of oxidative lesions, gene expression, growth regulation mitogenesis, inflammation, apoptosis and fibrosis leading to genomic instability and 
cancer progression. Chemical signals generated by dietary chemopreventive agents, anticancer agents, antioxidants and antioxidation enzymes, cause 
Nrf2 nuclear translocation that sets in motion a dynamic machinery of coactivators and corepressors that might form a multimolecular complex with 
Nrf2 for modulating transcriptional response through the antioxidant response element, ARE producing several phase II detoxification enzymes as 
stimulation of cellular defense system during stress. Oxidative stress might also cause release of NFκB from IκB and stimulate NFκB nuclear transloca-
tion to modulate transcriptional response through the NFκB response element. Several members of the MAPK family may act in concert with Nrf2 
and NFκB with multiple interactions between the members of the putative complex to elicit the chemopreventive and pharmacotoxicological events 
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